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February 2016 Abstracts S17mesenchymal markers, vimentin and N-cadherin in STM
cells. Enhanced invasion and migration capabilities were
observed in STM cells consistent with a mesenchymal
phenotype. Src has been shown to play a role in E-cadherin
regulation and EMT. Thus, treatment of cells with dasati-
nib, a Src inhibitor, suppressed cell growth in STM cells,
but not in ALKþ/TKI sensitive cell lines. The addition of a
low dose of dasatinib sensitized STM cells to the anti-
proliferative effects of crizotinib. STMcellswere subjected
to genetic analysis to identify new genetic anomalies that
could be driving resistance. Top hits are being evaluated.
To our knowledge, this is the ﬁrst report that demon-
strates EMT occurring in an ALKþ crizotinib resistant
clinical sample. Collectively these data support EMT as a
mechanism of resistance to crizotinib and identiﬁes
dasatinib as a potential therapeutic for treatment of cri-
zotinib resistance associated with EMT.
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Although PD-L1 immunohistochemical staining appears
to be a partially predictive biomarker of response to PD-1
inhibitors in some cancers, many PD-L1 positive tumors
do not respond to these agents. Possible explanations for
this observation are that some PD-L1 positive cancers
may have a paucity of inﬁltrating lymphocytes and/or T
cells within tumors may express multiple exhaustion
markers. We have developed a method for comprehen-
sive immune cell phenotyping using ﬂow cytometry on
solid tumors that have been dissociated into single cell
suspensions. Applying this technique to 33 resected ma-
lignant pleural mesothelioma samples, here we show that
compared to PD-L1 negative tumors, PD-L1 positive tu-
mors have signiﬁcantly more inﬁltrating CD45þ immune
cells, a signiﬁcantly higher proportion of inﬁltrating
CD3þ T cells, a signiﬁcant increase in proliferating CD4þ
and CD8þ T cells, and a signiﬁcantly higher percentage ofCD3þ cells displaying the activation antigens HLA-DRþ/
CD38þ. PD-L1 positive tumors also have a signiﬁcantly
higher proportion of FOXP3þ/CD4þ regulatory T cells.
We found that CD4þ and CD8þ T cells in PD-L1 positive
samples are signiﬁcantly more likely to express the T-cell
exhaustion markers PD-1 and TIM-3 compared to PD-L1
negative samples. Flow cytometric analysis also identi-
ﬁed two immunologically distinct PD-L1 positive meso-
thelioma samples: PD-1 positive, TIM-3 negative “single
positive” tumors, and PD-1 positive, TIM-3 positive
“double positive” tumors. Successful incorporation of
comprehensive immune proﬁling by ﬂow cytometry into
prospective clinical trials should hopefully reﬁne our
ability to predict which patients will respond to immune
checkpoint blockade and lead to rationally designed
combination immunotherapy trials.Novel epidermal growth factor
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Deaths from solid tumors are often not due to the pri-
mary lesion but to metastatic disease at distal sites such
as the lung, liver, and brain. Patients with non-small cell
lung cancer (NSCLC) experience brain metastases, a poor
prognostic marker, at an incidence rate of 30-50%. A
signiﬁcant proportion of the metastatic tumors express
activating mutations of the EGFR, including exon 19
deletions, which confer increased sensitivity to EGFR
inhibitors such as erlotinib and geﬁtinib. Despite suc-
cessful use of small molecule kinase inhibitors for the
treatment of EGFRþ primary lung tumors, current
therapeutics poorly inhibit the growth of NSCLC brain
metastases due to difﬁculty crossing the blood-brain
barrier. For this reason, NSCLC patients with brain me-
tastases are often excluded from clinical trials with novel
therapies and thus have access to very few emerging
treatment options.
We have synthesized a novel class of compounds that
inhibit the epidermal growth factor receptor (EGFR) in
the nanomolar range in vitro, and demonstrate a high
degree of selectivity for EGFR family members. The
parent compound, LL001, from Capella Therapeutics,
Inc., inhibited EGFR-mediated autophosphorylation and
